Inequitable Conduct Ruling Survives Sanofi Fed. Circ. Appeal
A decision that two patents for Sanofi-Aventis SA's lucrative cancer drug Taxotere were unenforceable stands up even under the rigorous standard for proving inequitable conduct in patent cases that the Federal...To view the full article, register now.
Already a subscriber? Click here to view full article